75 Results for "

Lewis

" in MedChemExpress (MCE) Product Catalog:
Products (75)

75 Results for "Lewis" in MCE Product Catalog:

Cat. No.: HY-125871
CAS No.: 70402-10-7
Neopatulin is a redox isomer and pivotal biogenetic precursor of the potent antibiotic patulin, which is produced by numerous fungal species. Neopatulin can be synthesized through Lewis acid-catalyzed aldol reaction or 2-formyl-1,3-dithiane with 2-(tert-butyldimethylsiloxy)-4-[(tert-butyldimethylsiloxy)-methyl]furan .
loading...
    loading...
Cat. No.: HY-182071
CAS No.: 2349329-01-5
Research Areas:  

Cancer

MG16 is a prodrug of 10-Methoxycamptothecin (HY-N0446). MG16 downregulates CDK6 and upregulates ASK1. MG16 induces cell cycle arrest and Apoptosis. MG16 exhibits anticancer activity against Lewis lung carcinoma, small cell lung cancer, and non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-158495
Synonyms: A2 N-linked oligosaccharide, 2-AA labelled
A2[3]G1 & A2[6]G1 glycan (G1), 2-AB labeled Lewis sugar. SLeX is a ligand for the cell adhesion molecule E-selectin (E-selectin), which is specifically expressed at sites of inflammatory lesions. Designing SLeX-polysaccharide conjugates to deliver drugs to inflammatory lesions .
loading...
    loading...
Cat. No.: HY-158522
Synonyms: A2[3]G1 & A2[6]G1 N-linked oligosaccharide, 2-AB labelled
A2[3]G1 & A2[6]G1 glycan (G1), 2-AB labeled Lewis sugar. SLeX is a ligand for the cell adhesion molecule E-selectin (E-selectin), which is specifically expressed at sites of inflammatory lesions. Designing SLeX-polysaccharide conjugates to deliver drugs to inflammatory lesions .
loading...
    loading...
Cat. No.: HY-101145
CAS No.: 1001478-90-5
Research Areas:  

Cancer

CK37 is a competitive choline kinase-α inhibitor. CK37 inhibits purified recombinant human choline kinase-α activity. CK37 suppresses MAPK and PI3K/AKT signaling, disrupts actin cytoskeletal organization. CK37 diminishs activating phosphorylations of ERK. CK37 exhibits anticancer activity against cervical cancer, melanoma, Lewis lung carcinoma, lung adenocarcinoma, breast cancer, and leukemia .
loading...
    loading...
Cat. No.: HY-110288R
CAS No.: 117405-58-0
Research Areas:  

Metabolic Disease

3FAx-Neu5Ac (Standard) is the analytical standard of 3FAx-Neu5Ac (HY-110288). This product is intended for research and analytical applications. 3FAx-Neu5Ac (Compound 8), a Sialic acid peracetylated analog, is a sialyltransferase inhibitor. 3FAx-Neu5Ac substantially reduces expression of the sialylated ligand sialyl Lewis X .
loading...
    loading...
Cat. No.: HY-101927
CAS No.: 2101736-25-6
Research Areas:  

Cancer

NOD1/2 antagonist-2 (Compound 26BH) is a dual NOD1/NOD2 antagonist (IC50s: 2.36 μM and 4.16 μM for NOD1 and NOD2, respectively). NOD1/2 antagonist-2 inhibits both NF-κB and MAPK inflammatory signaling, thereby sensitizing Paclitaxel (HY-B0015) to suppress Lewis lung carcinoma growth .
loading...
    loading...
Cat. No.: HY-165394
CAS No.: 129724-42-1
Melafolone is a potent dual COX-2/EGFR inhibitor with IC50s of 13.2 μM (COX-2) and 17.4 μM (EGFR). Melafolone enhances the effect of anti-PD-1 through vascular normalization and PD-L1 downregulation via the PI3K/Akt pathway in Lewis lung carcinoma (LLC) and CMT167 models. Melafolone can be used for lung cancer research .
loading...
    loading...
Cat. No.: HY-184488
CAS No.: 1640353-78-1
Target:  

DNA Methyltransferase

Research Areas:  

Cancer

AT-1965 is a selective CMTR2 inhibitor that suppresses methyltransferase activity. AT-1965 triggers the intrinsic antiviral immune response in cancer cells, promotes the infiltration and activation of B cells into tumors, and thereby induces antitumor immune memory to prevent tumor recurrence. AT-1965 can be formulated into lipid nanoparticles to achieve rapid tumor regression. AT-1965 is widely used in studies of immunologically "cold" tumors, triple-negative breast cancer, melanoma, Lewis lung cancer, and other malignancies .
loading...
    loading...
Cat. No.: HY-181477
ERK5-IN-7 is an orally active ERK5 inhibitor with an IC50 of 403.4 nM. ERK5-IN-7 directly inhibits ERK5 kinase activity, and downregulates the phosphorylation level and total protein expression of ERK5. ERK5-IN-7 induces Apoptosis (upregulates Bax, downregulates Bcl-2, and induces Caspase-3 cleavage). ERK5-IN-7 induces ROS accumulation. ERK5-IN-7 exhibits anticancer effects against Lewis lung cancer .
loading...
    loading...
Cat. No.: HY-L924
1,488 compounds

Boronic acid and boronic ester represent a relatively novel and promising chemical structure in drug design. Boronic acid exists in an sp²-hybridized state, possessing an empty p-orbital that can act as a Lewis acid to accept lone pairs from heteroatoms (O, N, or S). This Lewis acidity enables it to form reversible covalent bonds with amino acid residues such as lysine, serine, threonine, and histidine. Currently, five FDA-approved drugs containing boronic acid or boronic ester predominantly involve such covalent binding mechanisms in their interactions with target proteins. Furthermore, boronic acid can serve as a bioisostere for carboxylic acids, phosphates, and phenolic groups, utilized to improve pharmacokinetic properties and enhance drug efficacy.

To date, five boron-containing drugs have been approved by the FDA. The unique properties of boronic acids and boronic esters confer significant potential in drug design, with applications spanning cancer therapy (e.g., multiple myeloma), anti-infectives (e.g., fungal infections, tuberculosis), anti-inflammatory treatments (e.g., atopic dermatitis), antibacterial agents (e.g., carbapenem-resistant bacterial infections), and Reactive Oxygen Species (ROS)-responsive prodrugs, among others. The MCE Boronic Acid/Boronic Ester Fragment Library, which contains 1,488 compounds, serves as a valuable tool for the development of boron-containing drugs.

Cat. No.: HY-119169A
CAS No.: 83086-73-1
Synonyms: R 46846 hydrochloride
Tubulozole hydrochloride (R 46846 hydrochloride) is an orally active inhibitor of tubulin polymerization with an ID50 of 0.34 μM. Tubulozole hydrochloride induces activation of the Chk1 kinase and phosphorylation of ERK1/2, which is required for microtubule formation. Tubulozole hydrochloride arrests Mitosis at the metaphase stage. Tubulozole hydrochloride causes cells to accumulate in the radiosensitive mitotic phase of the cell cycle. Tubulozole hydrochloride exerts anticancer activity against colon cancer. Tubulozole hydrochloride produces a radiosensitizing effect in mouse tumor models and enhances the tumor growth delay effect when combined with γ-ray irradiation. Tubulozole hydrochloride is used in studies related to colon cancer, fascioliasis, MO4 fibrosarcoma, and Lewis lung carcinoma .
loading...
    loading...
Cat. No.: HY-106289
CAS No.: 105026-50-4
Target:  

Antibiotic

Research Areas:  

Cancer

Antibiotic MX 2 is an orally active antibiotic that can cross the blood-brain barrier. Antibiotic MX 2 inhibits the growth of drug-sensitive and multidrug-resistant tumor cells, prolongs the survival of tumor-bearing mice, induces single-strand and double-strand DNA breaks, suppresses colony formation of fresh human-derived tumor cells, and overcomes multidrug resistance mediated by P-glycoprotein. Antibiotic MX 2 can be used in research related to L1210 leukemia, Lewis lung cancer, colon adenocarcinoma type 26 and type 38, gastric adenocarcinoma, non-small cell lung cancer, mammary adenocarcinoma, drug-resistant P388 leukemia, renal cancer, melanoma, ovarian cancer, breast cancer, small cell lung cancer, and colorectal cancer .
loading...
    loading...
Cat. No.: HY-P992323

Target:  

VEGFR Tie ERK

Research Areas:  

Cardiovascular Disease Cancer

BI-836880 is a humanized bispecific nanobody and a selective inhibitor of VEGF and ANG2, with a Kd of 16 pM for hANG2, an EC50 of 1.4 nM for VEGF165, and an EC50 of 2.3 nM for VEGF121. BI-836880 blocks ERK phosphorylation downstream of VEGF-A as well as TIE2 phosphorylation downstream of ANG2. BI-836880 does not inhibit ANG1-mediated TIE2 phosphorylation. BI-836880 exerts anti-angiogenic effects, reduces the number of immature endothelial vessels in tumor tissues, and inhibits tumor growth in preclinical models. BI-836880 can be used in the research of pancreatic cancer, non-small cell lung cancer, renal cell carcinoma, ovarian cancer, colon cancer, and Lewis lung cancer .
loading...
    loading...
Cat. No.: HY-159803
CAS No.: 128201-92-3
Synonyms: 6-O-(3-Ethoxypropionyl)-3',4'-O-exo-benzylidenechartreusin
Target:  

Endogenous Metabolite

Research Areas:  

Cancer

IST-622 (6-O-(3-Ethoxypropionyl)-3',4'-O-exo-benzylidenechartreusin) is an anti-tumor agent with significant growth inhibitory activity. IST-622 exhibits significant anti-tumor effects against a variety of mouse tumors such as P388 and L1210 leukemias, B16 melanoma, Lewis lung carcinoma, Colon 26 and Colon 38 adenocarcinomas, and M5076 reticulum cell sarcoma. IST-622 was orally administered and the results showed efficacy in different tumor types. In addition, IST-622 provided significant inhibitory effects against two human tumor xenograft models: large cell lung carcinoma (Lu-116) and gastric adenocarcinoma (St-4). IST-622 also exhibited significant growth inhibitory activity against P388 leukemia in vitro, with a half inhibitory concentration (IC50) more than 20 times lower than CT .
loading...
    loading...